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Sir,
The increasing incidence of carbapenem-resistant Klebsiella
pneumoniae is a major challenge to public health. Despite the fact
that the prevalence of carbapenemases among carbapenem-
resistant K. pneumoniae varies geographically, the incidence of OXA-
48-like enzymes has soared in recent years and is particularly high in
some European countries, such as Spain and France (74% and 78%
among carbapenemase-producing K. pneumoniae, respectively).1 A
signiﬁcant number of OXA-48 variants have been reported in
the last decade. This includes OXA-232, a carbapenemase ﬁrstly
identiﬁed in France in 20112 and thereafter found in several coun-
tries.3,4 Recently, an MDR K. pneumoniae ST231 co-producing OXA-
232, the ESBL CTX-M-15 and the 16S rRNA methyltransferase RmtF
conferring broad-spectrum resistance to aminoglycosides has
emerged as a successful epidemic clone in South-East Asia, with
related outbreaks being reported in Singapore and in Brunei
Darussalam between 2013 and 2015.5,6 Here, we report on a noso-
comial spreadof this emerging resistant strain in Switzerland.
Six K. pneumoniae clinical isolates with reduced susceptibility or
resistant to carbapenems were recovered from February to April
2017 from ﬁve different patients, namely three hospitalized in the
medicine ward of a regional hospital in Western Switzerland, and
two non-hospitalized at the private Ear, Nose and Throat (ENT)
centre located near to the hospital (Table 1) and were sent to the
Swiss National Reference Center for Emerging Antibiotic
Resistance for further characterization. All the patients reported no
recent travel abroad. Clinical and epidemiological analyses failed
to detect any obvious route of transmission for those isolates.
Antimicrobial susceptibility testing was performed by disc
diffusion assay (Sanoﬁ-diagnostic Pasteur, France) and MICs
were determined using Etest (bioMe´rieux, France) and broth micro-
dilution techniques, with susceptibility deﬁned according to CLSI
breakpoints (https://clsi.org/standards/products/microbiology/docu
ments/m100/). Four isolates were resistant to penicillins, broad-
spectrumcephalosporins,meropenemandertapenemandshowed
intermediate resistance to imipenem. The remaining two isolates
displayed a typical ESBL phenotype, with resistance towards all
penicillins, to expanded-spectrum cephalosporins (antagonized
by b-lactamase inhibitors) and to ertapenem, and susceptibility to
imipenem and meropenem. Interestingly, one isolate presenting
carbapenemase activity and one exhibiting an ESBL phenotype had
been recovered froma single patient (Table 1). All six K. pneumoniae
isolates also exhibited broad-spectrum resistance to aminoglyco-
sides and were additionally resistant to sulphonamides, ﬂuoro-
quinolones, trimethoprim/sulfamethoxazole, chloramphenicol,
tetracycline and to the recently developed ceftolozane/tazobactam
combination. Notably, all six clinical isolates were susceptible to
colistin and to the ceftazidime/avibactamcombination.
Multiplex PCRs performed to detect Ambler class A, B and D car-
bapenemases and 16S rRNA aminoglycoside resistance genes7,8
followed by sequencing revealed that all six isolates possessed the
rmtF 16S rRNA methyltransferase gene, and that the four
carbapenem-resistant isolates possessed the blaOXA-232 carbape-
nemase gene. In addition, all the isolates possessed the ESBL
blaCTX-M-15 and the blaTEM-1 gene (Table 1). Transferability of the
blaOXA-232, blaCTX-M-15 and rmtF genes was attempted by mating-
out assays using the azide-resistant Escherichia coli J53 as a recipi-
ent strain. Transconjugants were obtained on azide (100 mg/L)
and either amikacin/gentamicin (50 mg/L each) or ceftazidime
(1mg/L), but not imipenem (1mg/L), indicating the transferability
of the plasmids harbouring the rmtF and blaCTX-M-15, but not that
one carrying the blaOXA-232 gene. Analysis of the plasmid content
by using the Kieser technique revealed the presence of several
plasmids in all isolates. The blaOXA-232 was carried on a 6141 bp
plasmid identical to that identiﬁed by Potron et al.,2 as further sup-
ported by sequence analysis performed as previously reported.6
Noticeably, the rmtF and blaCTX-M-15 genes were located on the
same 160 kb plasmid. PFGE of the SpeI-digested genomic DNA ob-
tained from the six K. pneumoniae isolates revealed that theywere
clonally related. MLST showed that they belonged to ST231
(https://cge.cbs.dtu.dk/services/MLST/).
In an attempt to unravel the genetic factors contributing to the
emergence and spread of this multiresistant pathogen, WGS of
genomic DNA from isolate Kp1 (KP06–2017) was performed using
a MiniSeq system (Illumina, USA), generating a total of 13078950
reads with an average length of 145.8 bp. Reads were de novo
assembled using CLC Genomics Workbench version 7.5.1 (Qiagen,
France). The draft genome revealed a size of 6015778 bp, with an
average GC content of approximately 57%. The antimicrobial resis-
tome was identiﬁed using ResFinder9 and comprises genes
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conferring resistance to aminoglycosides (rmtF, aadB, aadA2 and
aacA4), b-lactams (blaOXA-232, blaCTX-M-15, blaTEM-1b), ﬂuoroquino-
lones [aac(60)Ib-cr], macrolides, lincosamides and streptogramin
B (MLS) [erm(B) and mph(A)], phenicols (catA1 and catB4), sul-
phonamides (sul1), trimethoprim (dfrA12) and rifampicin (arr-2)
(Table 1). Plasmid ﬁnder10 revealed the presence of IncFIB(pQil),
IncFII(K), IncFII(pRSB107), IncFIA and ColKP3 replicons; the latter
two present in the plasmids carrying the rmtF/blaCTX-M-15 and
blaOXA-232 genes, respectively.
Overall, to our knowledge, we report here the ﬁrst occurrence in
Europe of an MDR K. pneumoniae ST231 clone, so far geographic-
ally conﬁned in South-East Asia. This represents an important and
worrying step toward the rise of another epidemic cloneas a global
public threat.
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Table 1. Characteristics of the Klebsiella pneumoniae isolates under study
Isolate Ward Specimen
Date of
isolation ST
b-
Lactamases
identiﬁed
by PCR
Approximate
sizes of
plasmids (kb)
MIC (mg/L)
carbapenems
colistin
novel cephalosporin/b-lactamase
inhibitor combinations
IPM MEM ETP
ceftolozane/
tazobactam
ceftazidime/
avibactam
Kp1 ENT sinus swab 28/02/17 231 blaOXA-232,
blaCTX-M-15,
blaTEM-1b
3.6, 6.1, 9, 70,
160
2 8 .256 2 .256 2
Kp2 ENT sinus swab 09/03/17 231 blaOXA-232,
blaCTX-M-15,
blaTEM-1b
3.6, 6.1, 9, 70,
160
2 8 .256 2 .256 2
Kp3 Medicine urine 21/03/17 231 blaCTX-M-15,
blaTEM-1b
3.6, 4.8, 9, 70,
160
0.38 0.25 2 2 .256 2
Kp4 Medicine rectal swab 23/03/17 231 blaOXA-232,
blaCTX-M-15,
blaTEM-1b
3.6, 6.1, 9, 70,
160
2 8 .256 2 .256 2
Kp5 Medicine rectal swab 29/03/17 231 blaCTX-M-15,
blaTEM-1b
3.6, 4.8, 9, 70,
160
0.38 0.25 2 2 .256 2
Kp6 Medicine rectal swab 10/04/17 231 blaOXA-232,
blaCTX-M-15,
blaTEM-1b
3.6, 6.1, 9, 70,
160
2 8 .256 2 .256 2
IPM, imipenem; MEM, meropenem; ETP, ertapenem.
2
htt
p:/
/do
c.r
ero
.ch
